Glutamate (Metabotropic) Group II Receptors
Metabotropic Glutamate (mGlu) group II receptors are members of the metabotropic class of glutamate receptors, which also includes mGlu group I and mGlu group III receptors. Group II receptors are divided into two subtypes, mGlu2 and mGlu3.
Glutamate (Metabotropic) Group II Receptor Agonists |
|
|---|---|
| Cat. No. | 产品名称/活性 |
| 0187 | (±)-trans-ACPD |
| Group I and II mGlu agonist | |
| 1208 | (2R,4R)-APDC |
| Highly selective group II agonist | |
| 0323 | (S)-4-Carboxyphenylglycine |
| Weak group II mGlu agonist; also Group I mGlu antagonist | |
| 0333 | L-CCG-l |
| Potent group II mGlu agonist | |
| 0975 | DCG IV |
| Highly potent group II mGlu agonist; also NMDA agonist | |
| 3246 | LY 354740 |
| Potent and highly selective group II mGlu agonist | |
| 2453 | LY 379268 |
| Highly selective group II mGlu agonist | |
| 5064 | LY 379268 disodium salt |
| Selective group II mGlu agonist; sodium salt of LY 379268 (Cat. No. 2453) | |
Glutamate (Metabotropic) Group II Receptor Antagonists |
|
| Cat. No. | 产品名称/活性 |
| 1209 | LY 341495 |
| Highly potent and selective group II mGlu antagonist | |
| 4062 | LY 341495 disodium salt |
| Potent and selective group II mGlu antagonist; disodium salt of LY 341495 (Cat. No. 1209) | |
| 2913 | Ro 64-5229 |
| Selective, non-competitive mGlu2 antagonist | |
Glutamate (Metabotropic) Group II Receptor Modulators |
|
| Cat. No. | 产品名称/活性 |
| 4048 | BINA |
| Selective positive allosteric modulator of mGlu2 receptors | |
| 3283 | LY 487379 hydrochloride |
| Selective positive allosteric modulator of mGlu2 receptors | |
| 4982 | ML 337 |
| Selective negative allosteric modulator of mGlu3 receptors | |
| 4388 | MNI 137 |
| Selective negative allosteric modulator of group II mGlu receptors | |
| 5362 | TASP 0433864 |
| Selective positive allosteric modulator of mGlu2 receptors | |
| 6928 | VU 6001966 |
| Potent and selective negative allosteric modulator of mGlu2 receptors | |
Metabotropic Glutamate (mGlu) group II receptors are members of the metabotropic class of glutamate receptors, which also includes mGlu group I and mGlu group III receptors. Group II receptors are divided into two subtypes, mGlu2 and mGlu3. mGlu group II receptors are coupled to Gi/o, which inhibits adenylyl cyclase, decreasing the formation of cAMP. These receptors are involved in presynaptic inhibition and do not appear to affect postsynaptic membrane potential by themselves. The human genes for mGlu2 and mGlu3 receptors have been localized to chromosomes 3 (p21.1) and 7 (7q21.1-q21.2) respectively.
External sources of pharmacological information for Glutamate (Metabotropic) Group II Receptors :
Literature for Glutamate (Metabotropic) Group II Receptors
Tocris offers the following scientific literature for Glutamate (Metabotropic) Group II Receptors to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Metabotropic Glutamate Receptors Scientific Review
Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Our Metabotropic Glutamate Receptor review gives an overview of the pharmacological ligands used to study the mGlu receptors.
Request copyRequest PDF
Written by Prof David Nutt, this poster summarizes the brain circuits and neurotransmitter systems that are affected by the main classes of addictive drugs.
Request copyDownload PDFWritten by P. Skolnich et al
Our Depression poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder.
Request copyDownload PDFWritten by Anthony H.V. Schapira
Our Parkinson's disease (PD) poster summarizes the neurobiology of the disease, and highlights current therapeutic treatments for symptomatic PD.
Request copyDownload PDF